Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials

 
• By Derrick Gingery

Researchers find no significant difference in number of rare pediatric disease treatments starting clinical development before or after incentive was created, but advocates aren't ready to give up on the program yet.

incentive business concept as a group of businessmen and businesswomen run on a track towards a dangling carrot on a moving cable
Are there more trials on the track now that there's a PRV carrot at the end?

More from Review Pathways

More from Pathways & Standards